[CAS NO. 146062-49-9] MSDC-0160
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [146062-49-9]
Store
Catalog
SLK-S7453
Brand
Selleck
CAS
146062-49-9
DESCRIPTION [146062-49-9]
Overview
| MDL | MFCD00916084 |
|---|---|
| Molecular Weight | 370.42 |
| Molecular Formula | C19 H18 N2 O4 S |
| SMILES | C(C1SC(=O)NC1=O)C2=CC=C(OCC(=O)C3=CC=C(CC)C=N3)C=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6996 mL | 13.4982 mL | 26.9964 mL |
| 5 mM | 0.5399 mL | 2.6996 mL | 5.3993 mL |
| 10 mM | - | - | - |
| 50 mM | - | - | - |
Description
MSDC-0160 (CAY10415) is a prototype -modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease. Phase 2.
Targets
| mTOT [1] |
In vitro
MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis.
In vivo
MSDC-0160 (100 mg/kg p.o.) improves insulin sensitivity by resulting in the large decrease in the product of circulating insulin and glucose in diabetic KKAy mice.
References
Synonyms
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-
5-[[4-[2-(5-Ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione
CAY 10415
Mitoglitazone
MSDC 0160
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.